New hope for advanced cervical cancer: testing a promising drug duo
NCT ID NCT04906993
Summary
This large, late-stage study is comparing a new two-drug combination (camrelizumab and famitinib) against standard platinum-based chemotherapy for women with recurrent or metastatic cervical cancer. The main goals are to see if the new combination helps patients live longer without their cancer getting worse and if it is safe. The study has finished enrolling its 443 participants and is now in the follow-up phase.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.